Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
Details : CER-1236 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 19, 2025
Lead Product(s) : CER-1236
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CERo Publishes Preclinical Data Supporting CER-1236 for AML Treatment
Details : CERo anticipates initiating clinical trials for its lead product candidate, CER-1236. Currently, it is being evaluated on the IND enabling stage for the treatment of Acute Myeloid Leukemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 07, 2024
Lead Product(s) : CER-1236
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed,Olaparib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CERo’s technology aims to expand the therapeutic potential of CER T cell engineered-based therapies by introducing distinct and complementary tumor cell clearance pathways into a single T cell.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : Undisclosed,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable